Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To benefit from the vastly improved business climate in Quebec, Theralase Technologies Corporation. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) announced today that it’s partnering with JSS Scientific Research Corporation. (“JSS”), a Montreal based Contract Research Organization (“CRO”), to see and supply guidance within the completing a Food and drug administration / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will assess the safety and effectiveness of Theralase’s innovative Photo Dynamic Therapy (“PDT”) platform within the destruction of bladder cancer. Theralase anticipates executing further contracts within the Quebec biotech sector worth into the millions dollars within the next 12 to 18 several weeks.
Bladder cancer may be the fifth most typical cancer (4th for males, eighth for ladies), probably the most costly cancer to deal with, costing between $100k and $200k per patient and it has the greatest recurrence rate at 80%. In america alone, bladder cancer costs an believed $4B to deal with and you will find roughly 75,000 new cases each year with 15,000 deaths. Worldwide, you will find 386,000 new cases annually. Risks for bladder cancer more and more are now being associated with smoking, as countries having a greater prevalence of smoking have shown greater rates of bladder cancer. Theralase has discovered cure that destroys cancer cells and prevents their reoccurrence during preclinical testing and it is rapidly evolving to human numerous studies.
The World and Mail reported on September 8, 2014 that Canada is experiencing a significant lack of an important drug to treat bladder cancer. The shortfall, which is a result of manufacturing problems at plants run by two different pharmaceutical companies, might have major effects for patients. With no drug, bacillus Calmette-Guerin (“BCG”) to manage their signs and symptoms, some patients may need surgery to get rid of their bladders. If Theralase is effective in the human numerous studies in bladder cancer, this might help to alleviate the reliance upon BCG.
Theralase made a decision to work with JSS for many reasons. First of all, JSS has generated its status around the effective design, execution, analysis and publication of Food and drug administration and Health Canada-approved human numerous studies. Over the past 5 years and as a result of its client’s demands, JSS has dramatically expanded its operations and presently conducts studies in The United States, South America, Asia and europe. The current merger with Integrated Research Corporation., in 2014, a Montreal-based CRO, consolidated its position because the largest Canadian owned CRO and considerably enhanced its abilities within the conduct of phase I, II and III studies.
Next, the current positive alterations in stability running a business climate in Quebec, along with the election of the new premier, Philippe Couillard, an old neurosurgeon, who’s both pro-business and pro-biotech in Quebec have been factors within the selection.
Theralase promises to continue to purchase the Quebec biotech market because the development and research progresses and when these studies is effective, Theralase intends to invest huge amount of money in to the
infrastructure of Quebec supplying numerous high having to pay, white-colored collar jobs for that province, because it commercializes this cutting edge technology.
Theralase is finishing its preclinical development focus on its PDT platform in 2014 and intends to test its lead Photo Dynamic Compound (PDC) in bladder cancer at the begining of 2015. Theralase’s leading PDCs are presently being evaluated for safety and preclinical effectiveness by Princess Margaret Cancer Center, College Health Network (“UHN”) and also the College of Toledo under separate research contracts. The outcomes of those research contracts determines which lead Theralase PDC is going to be evaluated in human application inside a Food and drug administration / Health Canada Phase I/IIa clinical study for bladder cancer at the begining of 2015.
Dr. John S. Sampalis, President and Chief executive officer of JSS Scientific Research mentioned, “As a CRO that’s itself entrepreneurial and dedicated to innovative research, we’re genuinely happy to have met a skilled group like Theralase who’re also dedicated to exactly the same concepts of innovation and excellence. We expect to working together and supporting Theralase to create their novel therapy to Canadian and worldwide markets.”
Joanne Watson, Chief Business Officer of JSS Scientific Research mentioned, “With our previous clinical research experience in Photo Dynamic Therapy, and our ongoing collaborations inside the research community, we is really a logical fit for Theralase.”
Roger Dumoulin-White-colored, President and Chief executive officer of Theralase Corporation. mentioned that, “Theralase spent lots of time to conduct detailed research in selecting a CRO, once we wanted to make sure that i was partnering using the best organization in a position to provide us the expert guidance we must have to become effective. We discovered that partner in Dr. Sampalis and JSS.”
Dr. Arkady Mandel, Chief Scientific Officer of Theralase mentioned, “I expect to championing the PDC anti-cancer project and dealing alongside with JSS as well as their group of experts within the effective completing a Food and drug administration / Health Canada Phase I/IIa clinical study for bladder cancer.”
About Theralase Technologies Corporation.
Founded in 1994, Theralase Technologies Corporation. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) designs, manufactures and markets patented super-pulsed laser technology employed for the removal of discomfort, decrease in inflammation and dramatic acceleration of tissue healing. Theralase has offered over 1,200 systems to licensed healthcare practitioners for example: physicians, chiropractors, physiotherapists and sports therapists. Theralase continues to be very effective in healing nerve, muscle and joint conditions in clinical practice and today Theralase’s scientists are investigating the use of its lasers within the destruction of cancer using specifically designed molecules known as Photo Dynamic Compounds (PDCs) which localize towards the DNA of cancer cells after which, when activated by light, destroy the cells of cancer.
More information can be obtained at www.theralase.com and www.sedar.com .
About JSS Scientific Research:
JSS Scientific Research is really a full-service Contract Research Organization using its corporate office in Montreal, Canada along with a regional office in Bogota, Colombia. The organization offers comprehensive clinical
trial management services, from study design to publication of results, in Phase I-IV trials across an extensive selection of therapeutic areas. Biotechnology companies depend around the company’s knowledgeable project teams, and it is customer-centric and versatile method of effectively conduct their critical early phase trials, while pharmaceutical companies can leverage its niche publish-marketing service choices. With science and clinical epidemiological expertise at its core, JSS Scientific Research is really a leader in Publish-Approval Clinical Epidemiology Studies (PACES) including Publish-Marketing Observational Studies, Health Outcomes Research and Health Financial aspects. Presently JSS Scientific Research is performing scientific studies in over 20 regions because of its clients, including the very best 25 global pharmaceutical companies and biotechnology/device companies, worldwide.
To learn more, visit www.jssresearch.com
This pr release contains forward-searching statements, which reflect their current expectations regarding future occasions. The forward-searching statements involve risks and uncertainties. Actual results could differ materially from individuals forecasted herein. The Organization disclaims any obligation to update these forward-searching statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is determined within the policies from the TSX Venture Exchanges) accepts responsibility for that adequacy or precision of the release.
To Learn More:
President & Chief executive officer, Theralase Technologies Corporation.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
SOURCE: Theralase Technologies Corporation.